MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Perlegen Sciences, which develops genetic tests that correlate genetic variation to predisposition to disease and drug response, announced today that it has added key positions to its commercial team in preparation for the launch of its lead product, MammaPLUS™, a breast cancer risk stratifier, in the second half of 2009. The company’s new director of product marketing, Susan Billat, and new director of managed care, Fran Strauss, will help lead Perlegen’s sales/marketing team to reach groups that serve women who may benefit from more specific information on their risk for sporadic, non-hereditary breast cancer, including physicians, payers and advocacy organizations.
